Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate

Arzneimittelforschung. 2005;55(7):376-81. doi: 10.1055/s-0031-1296875.


The bioavailability of the oral iron compound iron(II)-glycine sulfate (ferro sanol duodenal, FSD, 1 x 100 mg Fe/d) was studied in 56 patients with iron deficiency anaemia using a 59Fe-labelling technique and 59Fe-whole-body counting. This technique measures the individual iron loss and allows in patients with substantial blood loss under iron medication a reliable information on the bioavailability of the drug. In all patients, the increased loss of iron (mean 5.8 +/- 4.4 mg/d) was clearly compensated by the iron utilisation (mean: 11.1 +/- 5.6 mg/d) from a daily dosage of 100 mg iron from FSD. A significant increase in the haemoglobin concentration was observed within the monitored treatment period of 6-10 weeks (mean Hb increase from 10.7 +/- 1.7 to 12.1 +/- 1.8 g/dl). FSD has therefore documented a bioavailability of at least 11% from a single daily dose of 100 mg Fe and was effective in the treatment of the anaemia in almost all patients under study.

MeSH terms

  • Adult
  • Anemia, Iron-Deficiency / drug therapy
  • Anemia, Iron-Deficiency / metabolism*
  • Biological Availability
  • Female
  • Glycine / analogs & derivatives
  • Glycine / pharmacokinetics
  • Glycine / therapeutic use
  • Hemoglobins / metabolism
  • Humans
  • Intestinal Absorption
  • Iron Compounds / administration & dosage
  • Iron Compounds / pharmacokinetics*
  • Iron Compounds / therapeutic use
  • Iron Radioisotopes
  • Male
  • Whole-Body Counting


  • Hemoglobins
  • Iron Compounds
  • Iron Radioisotopes
  • iron-glycine chelate
  • Glycine